Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Study sponsor: Inhibrx Biosciences, Inc · INBX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2033-07Estimated
Enrollment · participants340Estimated
Source updated2026-11-06Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.